INNOVATE (VATE) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue was $236.6 million, down 34.5% year-over-year, with full year revenue at $1.1 billion; adjusted EBITDA for Q4 was $15 million and $71.3 million for the year.

• Net loss attributable to shareholders was $16.9 million ($1.29 per share) in Q4, with full year net loss at $35.8 million.

• Life Sciences and Spectrum segments posted strong revenue growth, while Infrastructure faced declines due to project completions.

• DBM Global maintained a $1.1 billion backlog at year-end and added over $500 million in new projects in Q1 2025.

• Total consolidated debt decreased by $54.5 million year-over-year, mainly due to DBM Global's working capital improvements.

Financial highlights

• Q4 2024 consolidated revenue was $236.6 million, down from $361 million in Q4 2023, mainly due to lower Infrastructure segment activity.

• Q4 net loss attributable to shareholders was $16.9 million, compared to $9.6 million in Q4 2023.

• Q4 adjusted EBITDA was $15 million, down from $21.5 million year-over-year.

• Cash and cash equivalents at year-end were $48.8 million, down from $80.8 million a year earlier.

• Total principal outstanding indebtedness at year-end was $668.3 million, down from $722.8 million a year earlier.

Outlook and guidance

• Infrastructure segment enters 2025 with a $1.1 billion backlog and over $500 million in new projects added post year-end.

• Management is optimistic about leveraging assets and executing strategic alternatives, especially in life sciences and infrastructure.

• Life Sciences anticipates further regulatory approvals and commercial expansion for MediBeacon and R2 Technologies.

• Spectrum expects continued OTA network expansion, new entrants, and regulatory changes that may benefit spectrum value.

• DBM Global aims to convert backlog to revenue and pursue new commercial and industrial opportunities, including data center and power infrastructure projects.